在严重创伤性脑损伤后的早期预防中使用Perampanel:与Levétiracetam进行了回顾性比较研究
Hidetaka Onda1,2, Takuya Nishino3, Shoji Yokobori2
1Department of Disaster and Emergency Medicine, Kochi University, Nankoku, Japan.
Neurotrauma reports
|October 15, 2025
概括
与 levetiracetam (LEV) 相比,Perampanel (PER) 在严重创伤性脑损伤 (TBI) 患者中显著降低了早期创伤后发作 (EPTS). 此外,PER还缩短了机械通风的持续时间,这表明它有可能成为预防发作的有价值的替代品.
科学领域:
- 神经科学是一个神经科学.
- 创伤护理 创伤护理
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重创伤性脑损伤 (TBI) 后的早期创伤后 (EPTS) 与不良的神经结果有关.
- 列维 (LEV) 是预防的常见选择,但珀兰 (PER) 是AMPA受体对抗剂,显示出神经保护的前景.
研究的目的:
- 为了比较Perampanel (PER) 与Levétiracetam (LEV) 在预防严重TBI后7天内EPTS的疗效.
- 评估二次结果,包括机械通风持续时间,住院时间和格拉斯哥结局量表 (GOS) 评分.
主要方法:
- 对200名患有严重TBI的成年患者进行回顾性队列研究,在受伤后12小时内接受LEV或PER单疗法.
- 统计分析包括Firth的后勤回归和治疗加权的逆概率 (IPTW),以调整混因子.
主要成果:
- 与LEV组 (15.9%) 相比,PER组 (1.8%) 的EPTS发病率明显较低.
- PER显示了发作风险的显著降低 (第一次调整的OR=0.158,p=0.007;IPTW OR=0.112,p=0.037).
- PER组显示机械通风持续时间较短 (IRR = 0.515,p=0.015),在GOS或住院期间没有显著差异. 没有报告任何不良事件.
结论:
- 佩拉曼内尔 (PER) 在减少严重TBI患者早期创伤后发作 (EPTS) 方面比莱维 (LEV) 更有效.
- PER的疗效和安全性概况表明它是急性TBI护理中发作预防的潜在有价值的替代品.
- 对PER在TBI管理中的作用进行进一步研究是有必要的.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
822
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
822
Epilepsy and Seizures: Overview
1.2K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
Antiepileptic Drugs: Glutamate Antagonists
893
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
893
Seizures: Classification
1.4K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.4K
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Antiepileptic Drugs: Potassium Channel Activators
632
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
632


